TBI Treatment: Nasal Spray Shows Promise
- A novel nasal spray may offer a future treatment for traumatic brain injury (TBI), according to Mass General Brigham researchers.
- The research focused on foralumab, a monoclonal antibody developed by Tiziana, which has undergone clinical trials for conditions like multiple sclerosis and Alzheimer's disease.Howard weiner, MD, co-director of...
- Saef Izzy, MD, a neurologist at Brigham and Women's Hospital, noted that traumatic brain injury is a leading cause of death and disability, with chronic inflammation being a...
A groundbreaking nasal spray shows remarkable promise for TBI treatment! This innovative approach, detailed in a recent Nature neuroscience study, targets neuroinflammation, significantly reducing central nervous system damage in mice.researchers observed improved neurological outcomes, paving the way for potential human trials. The anti-CD3 nasal spray, featuring foralumab (a monoclonal antibody), could revolutionize TBI treatments, offering hope where current options fall short. Traumatic brain injury, a leading cause of disability, may find its solution thanks to this research. The modulation of the immune response within the brain is key. News Directory 3 emphasizes the importance of this breakthrough. Discover what’s next as scientists prepare to test this spray on humans.
Nasal Spray Shows Promise for Traumatic Brain Injury Treatment
A novel nasal spray may offer a future treatment for traumatic brain injury (TBI), according to Mass General Brigham researchers. The study, published in Nature Neuroscience, found that the anti-CD3 nasal spray reduced damage to the central nervous system and improved behavior in a mouse model of TBI, suggesting a potential new therapeutic approach.
The research focused on foralumab, a monoclonal antibody developed by Tiziana, which has undergone clinical trials for conditions like multiple sclerosis and Alzheimer’s disease.Howard weiner, MD, co-director of the Ann Romney Center for Neurologic Diseases at BWH, said this could also be effective for intracerebral hemorrhage and stroke patients.
Saef Izzy, MD, a neurologist at Brigham and Women’s Hospital, noted that traumatic brain injury is a leading cause of death and disability, with chronic inflammation being a key factor. He added that currently, there is no treatment to prevent the long-term effects of traumatic brain injury.
Experiments on mice with moderate-to-severe TBI revealed that the nasal treatment facilitated interaction between regulatory cells and microglial immune cells in the brain, modulating the immune response.This modulation correlated with improved neurological outcomes, including reduced anxiety and cognitive decline, as well as enhanced motor skills, according to Izzy.
“Modulating the neuroinflammatory response correlated with improved neurological outcomes, including less anxiety, cognitive decline, and improved motor skills,” Izzy said.
What’s next
Researchers plan to translate these preclinical findings to human trials, with the hope that the nasal spray could eventually be administered on the sidelines to athletes with concussions. Weiner envisions a future where the treatment is readily available for various TBI patients.